Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) announced it has produced more than 1.3 metric tons of recombinant spider silk cocoons in a single month, establishing a new world record. This achievement represents a major step toward the industrial-scale commercialization of the advanced biomaterial. The company stated the milestone reflects the successful execution of its 2026 scale-up plan, with expanded facilities and BAM-1 Alpha production hybrids delivering consistent, high-output performance.
The company is now targeting ramping production to 10 metric tons per month to support applications across technical textiles and performance materials. Kraig Biocraft Laboratories is a reporting biotechnology company and the leading developer of genetically engineered spider silk-based fiber technologies. The company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. For more information, visit https://www.kraiglabs.com/.
This press release was distributed by InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. For more information, please visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
The record-setting production volume signals a pivotal shift from laboratory research to viable manufacturing capacity. For business and technology leaders, this development indicates that spider silk, long touted for its exceptional strength, elasticity, and lightweight properties, is transitioning from a scientific novelty to a commercially scalable material. The implications for industries ranging from aerospace and automotive to medical devices and high-performance apparel are substantial, as it opens the door to next-generation materials that could replace traditional synthetics and metals in specific applications.
The company's progress toward a 10-metric-ton monthly production target suggests a clear roadmap for market entry. This scale of production is necessary to meet the demands of industrial supply chains and could catalyze new product development across multiple sectors. The advancement also highlights the growing maturity of biotechnology and genetic engineering as tools for industrial material science, pointing to a future where biofabrication plays a central role in manufacturing.
